Business Context and Reporting Period
Quince Therapeutics, Inc. (QNCX) filed a Form 8-K on May 17, 2026, reporting the completion of a material definitive agreement and acquisition on May 18, 2026. The Company acquired Orphai Therapeutics, LLC (Orphai) and its parent, Orphai Holdings Therapeutics, Inc. (HoldCo), via a tax-free reorganization. This transaction significantly alters the Company's capital structure and strategic focus, centering on the development of LAM-001, an inhaled formulation of rapamycin for pulmonary vascular and fibrotic lung diseases.
Key Financial Metrics and Capital Structure
The filing details a significant capital raise and equity restructuring rather than operational financial performance metrics such as revenue or profit, which are not provided in this current report.
- Financing Proceeds: The Company entered into a Securities Purchase Agreement to sell PIPE Securities for an aggregate cash purchase price of approximately $115 million.
- Additional Potential Proceeds: Financing Warrants were issued to purchase additional Series C Preferred Stock, potentially generating up to an additional $72 million if exercised in full.
- Equity Issuance (Merger): The Company issued 3,258,517 shares of Common Stock and 67,101.235 shares of Series C Non-Voting Convertible Preferred Stock (convertible 1,000:1) to HoldCo stockholders.
- Equity Issuance (PIPE): The Company sold 144,200.633 shares of Series C Preferred Stock and warrants to purchase 72,100.322 shares of Series C Preferred Stock to Investors.
- Post-Transaction Ownership (Fully Diluted):
- Pre-transaction Quince equityholders: ~6.9%
- Former HoldCo/Orphai equityholders: ~31.9%
- PIPE Investors: ~61.2%
- Debt and Liquidity: The filing does not provide specific values for existing debt, cash on hand, or liquidity ratios prior to the transaction.
Material Changes Versus Prior Period
The primary material change is the acquisition of Orphai, which effectively results in a reverse merger scenario where former Orphai stakeholders and new PIPE investors hold the majority of the equity.
- Control Shift: Pre-transaction Quince shareholders were diluted from 100% ownership to approximately 6.9% of the fully diluted capitalization following the financing.
- Asset Acquisition: The Company now controls Orphai's assets, including the LAM-001 program, which has secured U.S. and EU orphan drug designations.
- Authorized Shares: The Company proposed amending its charter to increase authorized Common Stock from 250,000,000 to 800,000,000 shares.
- Option Pool: Options to purchase Orphai common stock were assumed and converted into options to purchase 26,332,798 shares of Quince Common Stock.
Guidance, Outlook, and Management Commentary
Management highlighted the strategic intent to build a focused, high-impact biotechnology company centered on LAM-001. The filing includes forward-looking statements regarding clinical timelines and regulatory expectations.
- Clinical Pipeline:
- LAM-001: An inhaled rapamycin formulation for pulmonary diseases.
- Ongoing Trials: Phase 2 trial in Bronchiolitis Obliterans Syndrome (BOS) post-lung transplant; Phase 2a data for pulmonary arterial hypertension and PH-ILD presented at the American Thoracic Society conference.
- Planned Trials: Phase 2 trials planned for PH-ILD and sarcoidosis-associated PH (SAPH).
- Management Changes:
- Brigette Roberts, M.D., former CEO of Orphai, was appointed to the Board of Directors and as Chief of Corporate Affairs.
- Retention bonuses of $700,000 (CEO Dirk Thye) and $500,000 (COO Brendan Hannah) were approved, contingent on employment through stockholder approval of the transaction.
- Lock-up Agreements: Key insiders are subject to a 12-month lock-up or until the top-line data of the LAM-001 Phase 2 trial is announced, whichever occurs first.
- Risks: Risks include the failure to consummate the financing, non-exercise of warrants, clinical trial failures, regulatory hurdles, and the ability to retain key personnel.
Important Facts for Investor Verification
- Stockholder Approval: The transaction requires stockholder approval for the conversion of Series C Preferred Stock, the merger, and the charter amendment. The filing notes a proxy statement will be filed.
- Warrant Exercise Conditions: Financing Warrants are exercisable only after the public announcement of top-line data from the LAM-001 Phase 2 trial or the trial's termination/suspension.
- Financial Statements: Pro forma financial information and financial statements of the acquired business are not included in this filing and are expected to be filed via amendment within 71 days.
- Series C Conversion: Series C Preferred Stock converts 1,000:1 into Common Stock but is subject to beneficial ownership limitations (4.99% to 19.99%) to prevent automatic conversion if it would exceed these thresholds.
- Use of Proceeds: The $115 million raised is intended to fund the development of LAM-001 and extend the Company's cash runway, though specific runway duration is not quantified in this text.